{"id":30245,"date":"2024-11-05T12:43:04","date_gmt":"2024-11-05T07:13:04","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=30245"},"modified":"2024-11-05T12:43:05","modified_gmt":"2024-11-05T07:13:05","slug":"pharma-news-for-prolong-shorla-novartis","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-prolong-shorla-novartis","title":{"rendered":"Prolong\u2019s PP-007 Fast-Tracked for Stroke; FDA Expands JYLAMVO Pediatric Approval; Corcept\u2019s Cushing\u2019s Drug Shows Positive Phase III Results; ESSA Halts Phase II Study of Masofaniten for Prostate Cancer; SCEMBLIX Approved for Leukemia"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a05e359bf00b\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a05e359bf00b\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-prolong-shorla-novartis\/#Prolong_Pharmaceuticals_Secures_FDA_Fast_Track_for_PP-007_in_Stroke_Therapy\" >Prolong Pharmaceuticals Secures FDA Fast Track for PP-007 in Stroke Therapy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-prolong-shorla-novartis\/#Shorla_Oncologys_JYLAMVO_Approved_by_FDA_for_Pediatric_Use\" >Shorla Oncology\u2019s JYLAMVO Approved by FDA for Pediatric Use<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-prolong-shorla-novartis\/#Corcept_Therapeutics_Reports_Positive_Phase_III_Results_for_Cushings_Syndrome\" >Corcept Therapeutics Reports Positive Phase III Results for Cushing\u2019s Syndrome<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-prolong-shorla-novartis\/#ESSA_Pharma_Ends_Phase_II_Trial_of_Masofaniten_with_Enzalutamide_in_Prostate_Cancer\" >ESSA Pharma Ends Phase II Trial of Masofaniten with Enzalutamide in Prostate Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-prolong-shorla-novartis\/#FDA_Approves_Novartis_SCEMBLIX_for_Leukemia_Treatment\" >FDA Approves Novartis\u2019 SCEMBLIX for Leukemia Treatment<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-prolong-pharmaceuticals-secures-fda-fast-track-for-pp-007-in-stroke-therapy\"><span class=\"ez-toc-section\" id=\"Prolong_Pharmaceuticals_Secures_FDA_Fast_Track_for_PP-007_in_Stroke_Therapy\"><\/span>Prolong Pharmaceuticals Secures FDA Fast Track for PP-007 in Stroke Therapy<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Prolong Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, announced that its investigational therapy, PP-007 (PEGylated carboxyhemoglobin, bovine), has been granted Fast Track designation by the FDA for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-ischemic-stroke-ais-market\" class=\"ek-link\">treatment of acute ischemic stroke<\/a>. This designation highlights the FDA\u2019s recognition of PP-007\u2019s potential to address critical needs in stroke treatment. The therapy is currently under evaluation in the ongoing HEMERA-1 clinical trial in the United States, focused on assessing its safety and efficacy.<\/p>\n\n\n\n<p>With over 700,000 ischemic strokes occurring each year in the U.S. alone, the demand for innovative stroke therapies remains high, especially given that around 50% of patients continue to experience lasting disabilities despite existing treatments like thrombolytic agents (TNKase\u00ae and Activase\u00ae) and mechanical thrombectomy (MT). Prolong Pharmaceuticals aims to address these limitations with PP-007, a therapy that not only improves oxygen delivery to hypoxic neurons but also has anti-inflammatory effects and a 24-hour duration of action, distinguishing it from other treatments in development.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Ronald Jubin, Ph.D., Vice President of Early Development at Prolong Pharmaceuticals, emphasized the promise of PP-007, stating, \u201cReceiving Fast Track designation underscores the groundbreaking potential of PP-007, backed by years of research. We believe no other stroke drug in development offers this unique combination: (1) opening collateral vessels, (2) selectively delivering oxygen to hypoxic neurons, (3) reducing inflammation, and (4) sustaining effects for 24 hours, as shown in pharmacokinetic studies with acute stroke patients. These capabilities, demonstrated in multiple PP-007 studies, are driving advances in stroke care and addressing critical unmet needs in acute ischemic stroke.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>In the ongoing HEMERA-1 trial, Principal Investigator Dr. Italo Linfante from Baptist Hospital in Miami noted positive patient outcomes. \u201cWe are increasingly encouraged by the promising 90-day mRS outcome measures achieved with PP-007 treatment in combination with IVT and MT, particularly as we expand enrollment to include patients with ASPECT scores ranging from 3 to 5,\u201d he shared. Reflecting on World Stroke Day, Dr. Kirsten Gruis, Chief Medical Officer at Prolong Pharmaceuticals, added, \u201cWe are excited to closely collaborate with the FDA to expedite the development of PP-007 to improve survival and quality-of-life outcomes in AIS patients.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-shorla-oncology-s-jylamvo-approved-by-fda-for-pediatric-use\"><span class=\"ez-toc-section\" id=\"Shorla_Oncologys_JYLAMVO_Approved_by_FDA_for_Pediatric_Use\"><\/span>Shorla Oncology\u2019s JYLAMVO Approved by FDA for Pediatric Use<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Shorla Oncology announced that the FDA has expanded the approval of JYLAMVO (methotrexate) to include treatment for pediatric patients with <a href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market\" class=\"ek-link\">acute lymphoblastic leukemia <\/a>and <a href=\"https:\/\/www.delveinsight.com\/report-store\/juvenile-idiopathic-arthritis-jia-market\" class=\"ek-link\">polyarticular juvenile idiopathic arthritis<\/a>. This expanded approval makes JYLAMVO the only oral liquid methotrexate on the market approved for both adult and pediatric use, marking a significant step forward in treatment accessibility for young patients with oncology and autoimmune needs.<\/p>\n\n\n\n<p>Originally approved by the FDA for adult use, JYLAMVO has been utilized to treat conditions such as <a href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market\">acute lymphoblastic leukemia<\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/mycosis-fungoides-market\" class=\"ek-link\">mycosis fungoides<\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-hodgkins-lymphoma-market\" class=\"ek-link\">non-Hodgkin lymphoma<\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/rheumatoid-arthritis-ra-market\" class=\"ek-link\">rheumatoid arthritis<\/a>, and <a href=\"https:\/\/www.delveinsight.com\/report-store\/moderate-to-severe-psoriasis-market\">severe psoriasis<\/a>. Its liquid form provides a practical alternative for those who struggle with pill-based medications, broadening treatment options for patients with chronic health needs. The approval builds on JYLAMVO\u2019s established role in adult care, now offering similar benefits to younger patients.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThis approval follows JYLAMVO\u2019s successful use in adult patients and represents a critical step forward in addressing the unmet needs of pediatric care in oncology and autoimmune diseases,\u201d said Sharon Cunningham, CEO of Shorla Oncology. \u201cWe are pleased to offer a convenient, patient-friendly alternative for both adult and pediatric patients in the U.S. as we continue to develop innovative solutions for those with limited treatment options.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Adding further details on JYLAMVO\u2019s design, Orlaith Ryan, Shorla Oncology\u2019s Chief Technical Officer and co-founder, shared, \u201cFor patients with chronic conditions including cancer, JYLAMVO offers a convenient, palatable option for patients who may have difficulty swallowing pills. At Shorla, we are committed to continuity of supply of age-appropriate formulations for patients in need.\u201d Additionally, Rayna Herman, Chief Commercial Officer of Shorla Oncology, highlighted JYLAMVO\u2019s three-month stability at room temperature after opening, adding, \u201cIn addition to its palatable formulation, JYLAMVO eliminates the need for refrigeration, which brings greater ease to patients and families.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-corcept-therapeutics-reports-positive-phase-iii-results-for-cushing-s-syndrome\"><span class=\"ez-toc-section\" id=\"Corcept_Therapeutics_Reports_Positive_Phase_III_Results_for_Cushings_Syndrome\"><\/span>Corcept Therapeutics Reports Positive Phase III Results for Cushing\u2019s Syndrome<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Corcept Therapeutics Incorporated reported strong third-quarter results for 2024, driven by increased patient and physician adoption of its flagship product, KORLYM, which treats hypercortisolism. The company\u2019s revenue rose to $182.5 million in Q3, up from $123.6 million in the same period last year, while net income reached $47.2 million. Corcept attributes this growth to greater awareness among physicians of the effects of hypercortisolism and the importance of early screening. The company\u2019s support systems for KORLYM continue to play a vital role in helping patients maximize the benefits of the treatment. The company also raised its 2024 revenue guidance to between $675 and $700 million.<\/p>\n\n\n\n<p>Looking ahead, Corcept anticipates a significant fourth quarter, with plans to submit a New Drug Application (NDA) for relacorilant as a <a href=\"https:\/\/www.delveinsight.com\/report-store\/cushings-syndrome-market\" class=\"ek-link\">treatment for patients with Cushing&#8217;s syndrome<\/a> and to release clinical trial data across multiple programs. By year-end, the company expects results from its CATALYST study for KORLYM in patients with hypercortisolism and type 2 diabetes, as well as from its ROSELLA study for relacorilant combined with nab-paclitaxel in ovarian cancer. Corcept will also release findings from DAZALS, its Phase II trial for dazucorilant in patients with ALS. These clinical developments signal Corcept\u2019s commitment to advancing treatment options for complex conditions linked to cortisol modulation.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Corcept CEO Dr. Joseph Belanoff highlighted the company\u2019s growing footprint in hypercortisolism care, saying, \u201cIn the third quarter, we added more KORLYM prescribers and more patients received KORLYM treatment than ever before. Physicians are increasingly aware of hypercortisolism\u2019s true prevalence and the negative health outcomes for patients who go untreated. Screening is becoming more common, and the number of patients receiving appropriate care continues to increase.\u201d He underscored the importance of Corcept\u2019s support services in optimizing patient outcomes, noting, \u201cFor patients and physicians who choose KORLYM, our extensive system of support services is critical to maximizing the benefit of our medication.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Chief Development Officer Bill Guyer, PharmD, expressed optimism about relacorilant\u2019s clinical potential, stating, \u201cThe positive results from our GRADIENT and GRACE studies in patients with Cushing\u2019s syndrome highlight relacorilant\u2019s promise as a significant advancement in treating this challenging disease. The data confirm clinically meaningful improvements in a broad range of hypercortisolism signs and symptoms without serious adverse effects.\u201d Dr. Guyer also discussed the upcoming results from the ROSELLA and DAZALS trials, noting, \u201cIf ROSELLA replicates the positive outcomes of our Phase II study, relacorilant could become a transformative treatment for patients with platinum-resistant ovarian cancer.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-essa-pharma-ends-phase-ii-trial-of-masofaniten-with-enzalutamide-in-prostate-cancer\"><span class=\"ez-toc-section\" id=\"ESSA_Pharma_Ends_Phase_II_Trial_of_Masofaniten_with_Enzalutamide_in_Prostate_Cancer\"><\/span>ESSA Pharma Ends Phase II Trial of Masofaniten with Enzalutamide in Prostate Cancer<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>ESSA Pharma Inc. has announced the termination of its Phase II trial investigating masofaniten combined with enzalutamide for <a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-castration-resistant-prostate-cancer-mcrpc-market\" class=\"ek-link\">patients with metastatic castration-resistant prostate cancer <\/a>who had not previously received second-generation antiandrogens. The decision was based on an interim analysis indicating a higher PSA90 response rate in patients on enzalutamide alone, the standard of care, compared to those on the combination therapy. Additionally, there was no observed efficacy benefit from combining masofaniten with enzalutamide. As a result, the company concluded the combination therapy was unlikely to meet the study\u2019s primary endpoint.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Dr. David Parkinson, CEO of ESSA, explained, \u201cOur commitment to delivering a meaningful clinical benefit to patients remains our highest priority, along with ensuring a robust safety profile. This decision, although difficult, was made in the best interest of patients and aligns with our clinical standards.\u201d Parkinson expressed gratitude to those involved, adding, \u201cWe are incredibly thankful to our partners, trial investigators, and especially the patients and families who participated in this study. Their contributions are invaluable as we continue to seek effective prostate cancer treatments.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The trial enrolled 52 patients from the United States, Canada, Australia, and France, aiming to compare the effects of the masofaniten-enzalutamide combination to enzalutamide monotherapy. Of those enrolled, 41 patients completed at least three months of follow-up, allowing the interim analysis to capture an early look at PSA response data. The safety profile of the combination therapy was consistent with previous studies, showing no new safety signals. ESSA\u2019s leadership emphasized the decision was necessary to focus resources on therapies with greater potential benefits for patients.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Chairman Richard Glickman reaffirmed ESSA\u2019s focus on strategic growth, stating, \u201cThe board, alongside senior management, is committed to preserving capital and exploring a range of options to maximize shareholder value.\u201d Glickman emphasized that the company would carefully consider the best next steps, saying, \u201cWe remain dedicated to leveraging our resources wisely to continue our work in prostate cancer treatment and other potential opportunities for ESSA.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-approves-novartis-scemblix-for-leukemia-treatment\"><span class=\"ez-toc-section\" id=\"FDA_Approves_Novartis_SCEMBLIX_for_Leukemia_Treatment\"><\/span>FDA Approves Novartis\u2019 SCEMBLIX for Leukemia Treatment<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The FDA has granted accelerated approval to Novartis&#8217; SCEMBLIX (asciminib) for adult patients newly diagnosed with <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-myeloid-leukemia-market\" class=\"ek-link\">Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP)<\/a>. This decision is based on results from the Phase III ASC4FIRST trial, which demonstrated superior major molecular response (MMR) rates at 48 weeks for SCEMBLIX compared to investigator-selected standard of care (SoC) tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib, dasatinib, and bosutinib. Continued approval for this indication may be contingent upon confirmatory results from further clinical evidence.<\/p>\n\n\n\n<p>The ASC4FIRST study showed nearly 20% more patients on SCEMBLIX reached MMR at 48 weeks compared to those on other SoC TKIs, and almost 30% more patients achieved MMR compared to imatinib alone. SCEMBLIX also demonstrated a favorable safety and tolerability profile, with fewer treatment-related adverse reactions (ARs), dose reductions, and discontinuations than other TKIs.&nbsp;<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>With this expanded indication, SCEMBLIX now becomes an option for a broader group of newly diagnosed Ph+ CML-CP patients, potentially improving long-term disease control. \u201cApprovals of new first-line treatments are crucial for patients,\u201d said Lee Greenberger, Chief Scientific Officer at The Leukemia &amp; Lymphoma Society. \u201cThis option could allow patients to better manage their disease while minimizing disruptive side effects.\u201d The most common adverse reactions reported included musculoskeletal pain, rash, fatigue, and headache, with no new safety issues observed.<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Victor Bulto, President of Novartis US, expressed pride in the company\u2019s commitment to CML treatment innovation: \u201cWith SCEMBLIX, we offer newly diagnosed patients a treatment option that balances efficacy and tolerability, possibly transforming the treatment journey for many living with CML.\u201d The ASC4FIRST trial continues, with additional data expected at the 96-week mark.<\/em><\/p>\n<\/blockquote>\n","protected":false},"excerpt":{"rendered":"<p>Prolong Pharmaceuticals Secures FDA Fast Track for PP-007 in Stroke Therapy Prolong Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, announced that its investigational therapy, PP-007 (PEGylated carboxyhemoglobin, bovine), has been granted Fast Track designation by the FDA for the treatment of acute ischemic stroke. This designation highlights the FDA\u2019s recognition of PP-007\u2019s potential to address critical [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":30246,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[20442,17564,22347,18982,768,204,704,5093,349,18962,420,2831,639,5587,5789,2019],"industry":[17225],"therapeutic_areas":[17240,17233,17227,17245,17228],"class_list":["post-30245","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-acute-ischemic-stroke","tag-acute-lymphoblastic-leukemia","tag-acute-lymphoblastic-leukemia-and-polyarticidiopathic-arthritis","tag-chronic-myeloid-leukemia","tag-cushings-syndrome","tag-delveinsight","tag-fda","tag-juvenile-idiopathic-arthritis","tag-latest-pharma-news","tag-metastatic-castration-resistant-prostate-cancer","tag-news","tag-non-hodgkin-lymphoma","tag-pharma-news","tag-psoriasis","tag-recent-pharma-news","tag-rheumatoid-arthritis","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-hematological-disorders","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-neurology","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Prolong, Shorla, Novartis<\/title>\n<meta name=\"description\" content=\"PP-007 Fast-Tracked, JYLAMVO Pediatric Approval, Corcept\u2019s Phase III Results, ESSA Halts Study, Novartis\u2019 SCEMBLIX\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-prolong-shorla-novartis\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Prolong, Shorla, Novartis\" \/>\n<meta property=\"og:description\" content=\"PP-007 Fast-Tracked, JYLAMVO Pediatric Approval, Corcept\u2019s Phase III Results, ESSA Halts Study, Novartis\u2019 SCEMBLIX\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-prolong-shorla-novartis\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-05T07:13:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-05T07:13:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/05124240\/Pharma-news-for-prolong-shorla-novartis.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Prolong, Shorla, Novartis","description":"PP-007 Fast-Tracked, JYLAMVO Pediatric Approval, Corcept\u2019s Phase III Results, ESSA Halts Study, Novartis\u2019 SCEMBLIX","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-prolong-shorla-novartis","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Prolong, Shorla, Novartis","og_description":"PP-007 Fast-Tracked, JYLAMVO Pediatric Approval, Corcept\u2019s Phase III Results, ESSA Halts Study, Novartis\u2019 SCEMBLIX","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-prolong-shorla-novartis","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-11-05T07:13:04+00:00","article_modified_time":"2024-11-05T07:13:05+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/05124240\/Pharma-news-for-prolong-shorla-novartis.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-prolong-shorla-novartis","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-prolong-shorla-novartis","name":"Pharma News | Prolong, Shorla, Novartis","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-prolong-shorla-novartis#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-prolong-shorla-novartis#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/05124240\/Pharma-news-for-prolong-shorla-novartis.png","datePublished":"2024-11-05T07:13:04+00:00","dateModified":"2024-11-05T07:13:05+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"PP-007 Fast-Tracked, JYLAMVO Pediatric Approval, Corcept\u2019s Phase III Results, ESSA Halts Study, Novartis\u2019 SCEMBLIX","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-prolong-shorla-novartis"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-prolong-shorla-novartis#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/05124240\/Pharma-news-for-prolong-shorla-novartis.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/05124240\/Pharma-news-for-prolong-shorla-novartis.png","width":772,"height":482,"caption":"Pharma-news-for-prolong-shorla-novartis"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/05124240\/Pharma-news-for-prolong-shorla-novartis-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Acute Ischemic Stroke<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Acute Lymphoblastic Leukemia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">acute lymphoblastic leukemia and polyarticidiopathic arthritis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Chronic Myeloid Leukemia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cushing&#039;s syndrome<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Juvenile Idiopathic Arthritis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">metastatic castration-resistant prostate cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-Hodgkin lymphoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Psoriasis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">rheumatoid arthritis<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Acute Ischemic Stroke<\/span>","<span class=\"advgb-post-tax-term\">Acute Lymphoblastic Leukemia<\/span>","<span class=\"advgb-post-tax-term\">acute lymphoblastic leukemia and polyarticidiopathic arthritis<\/span>","<span class=\"advgb-post-tax-term\">Chronic Myeloid Leukemia<\/span>","<span class=\"advgb-post-tax-term\">Cushing&#039;s syndrome<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Juvenile Idiopathic Arthritis<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">metastatic castration-resistant prostate cancer<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Non-Hodgkin lymphoma<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Psoriasis<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">rheumatoid arthritis<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Nov 5, 2024","modified":"Updated on Nov 5, 2024"},"absolute_dates_time":{"created":"Posted on Nov 5, 2024 12:43 pm","modified":"Updated on Nov 5, 2024 12:43 pm"},"featured_img_caption":"Pharma-news-for-prolong-shorla-novartis \n","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30245","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=30245"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30245\/revisions"}],"predecessor-version":[{"id":30247,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30245\/revisions\/30247"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/30246"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=30245"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=30245"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=30245"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=30245"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=30245"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}